Essex Testing Clinic, Inc.



## **FINAL REPORT**

# CLINICAL SAFETY EVALUATION REPEATED INSULT PATCH TEST

NCL Foaming Hand Soap 0424 Lot: 16-039-2

## **Sponsor**

National Chemical Laboratories, Inc. 401 N. 10<sup>th</sup> Street Philadelphia, PA 19123

**Sponsor Representative** 

John Bartusiak

**Clinical Testing Facility** 

Essex Testing Clinic, Inc. 799 Bloomfield Avenue Verona, NJ 07044

Sponsor Code: N56

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

**Date of Final Report** 

5-11-16

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

# SIGNATURE PAGE CLINICAL SAFETY EVALUATION REPEATED INSULT PATCH TEST

NCL Foaming Hand Soap 0424 Lot: 16-039-2

(f lu	5/4/16
John A. Erianne, MD	Date
Board-Certified Dermatologist	
Medical Investigator	

Essex Testing Clinic, Inc.

## **QUALITY ASSURANCE STATEMENT**

This study (ETC Panel Nos.: 16024/16097/16129/16131; ETC Entry No.: 29711) was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in 21 CFR Part 50 (Protection of Human Subjects – Informed Consent) and the Standard Operating Procedures of Essex Testing Clinic, Inc.

For purposes of this clinical study:

_X	Informed Consent was obtained.
	Informed Consent was not obtained.
_X	An IRB review was not required.
	An IRB review was conducted and approval to conduct the proposed clinical research was granted.

To assure compliance with the study protocol, the Quality Assurance Unit completed an audit of the applicable study records and report. This report is considered a true and accurate reflection of the testing methods and source data.

Shewi L &	auslis	7	may	20/6
Sherri L. Sayles, MS		Date	/-	
Manager, Quality Assurance	e Č			

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

## **TABLE OF CONTENTS**

1.0 OBJECTIVE	1
2.0 SPONSOR	1
2.1 Sponsor Representative	1
3.0 CLINICAL TESTING FACILITY	1
4.0 CLINICAL INVESTIGATORS	1
5.0 STUDY DATES	1
6.0 ETHICS	2
6.1 Ethical Conduct of the Study	2
6.2 Subject Information and Consent	2
7.0 TEST MATERIAL	2
8.0 TEST SUBJECTS	2
9.0 TEST PROCEDURE	3
9.1 Induction Phase	3
9.2 Challenge Phase	3
9.3 Data Interpretation	4
10.0 RESULTS AND DISCUSSION	4
11.0 CONCLUSIONS	4
TABLE 1 - INDIVIDUAL SCORES	

Page 1 of 4

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

# CLINICAL SAFETY EVALUATION REPEATED INSULT PATCH TEST

## NCL Foaming Hand Soap 0424 Lot: 16-039-2

#### 1.0 OBJECTIVE

The objective of this study was to determine the irritation and/or sensitization potential of the test article after repeated application under occlusive patch test conditions to the skin of human subjects (non-exclusive panel).

## 2.0 SPONSOR

National Chemical Laboratories, Inc. 401 N. 10<sup>th</sup> Street Philadelphia, PA 19123

#### 2.1 Sponsor Representative

John Bartusiak

## 3.0 CLINICAL TESTING FACILITY

The study was conducted by:

Essex Testing Clinic, Inc. 799 Bloomfield Avenue Verona, NJ 07044

## 4.0 CLINICAL INVESTIGATORS

Study Director:

Annemarie E. Hollenback, BA

Principal Investigator:

Toni F. Miller, PhD, DABT, BCFE

Medical Investigator:

John A. Erianne, MD, Board-Certified Dermatologist

## **5.0 STUDY DATES**

Study initiation:

January 13, 2016 (Panel No. 16024)

March 2, 2016 (Panel No. 16097)

March 16, 2016 (Panel Nos. 16129 and 16131)

Final evaluation:

February 19, 2016 (Panel No. 16024)

April 8, 2016 (Panel No. 16097)

April 22, 2016 (Panel Nos. 16129 and 16131)

Essex Testing Clinic, Inc.

Page 2 of 4

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

#### 6.0 ETHICS

## 6.1 Ethical Conduct of the Study

This study was conducted in accordance with the intent and purpose of Good Clinical Practice regulations described in Title 21 of the U.S. Code of Federal Regulations (CFR), the Declaration of Helsinki and/or Essex Testing Clinic (ETC) Standard Operating Procedures.

## **6.2 Subject Information and Consent**

This study was conducted in compliance with CFR Title 21, Part 50 (Informed Consent of Human Subjects). Informed Consent was obtained from each subject in the study and documented in writing before participation in the study. A copy of the Informed Consent was provided to each subject.

## 7.0 TEST MATERIAL

The test article used in this study was provided by:

National Chemical Laboratories, Inc. 401 N. 10<sup>th</sup> Street Philadelphia, PA 19123

It was received on January 7, 2016 and identified as follows:

ETC Entry No.	Test Article ID	<u>Description</u>
29711	NCL Foaming Hand Soap 0424 Lot: 16-039-2	Transparent Colorless Liquid*

<sup>\*</sup>The test article was prepared as a 1% aqueous (distilled water) solution and was shaken well prior to application to the patch.

#### **8.0 TEST SUBJECTS**

At least 200 male and female subjects ranging in age from 18 to 79 years were to be empanelled for this test.

The subjects chosen were to be dependable and able to read and understand instructions. The subjects were not to exhibit any physical or dermatologic condition that would have precluded application of the test article or determination of potential effects of the test article.

Essex Testing Clin	ic. Inc.

Page 3 of 4

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

## 9.0 TEST PROCEDURE

The 9 Repeated Insult (occlusive) Patch Test (9-RIPT)<sup>1</sup> was conducted as follows:

#### 9.1 Induction Phase

A sufficient amount of the test article (approximately 0.2 mL) was placed onto a Parke-Davis Readi-Bandage® occlusive patch (approximately 0.05 mL/cm² of test material), which was applied to the back of each subject between the scapulae and waist, adjacent to the spinal mid-line. This procedure was performed by a trained technician/examiner and repeated every Monday, Wednesday and Friday until 9 applications of the test article had been made.

The subjects were instructed to remove the patch 24 hours after application. Twenty-four hour rest periods followed the Tuesday and Thursday removals and 48-hour rest periods followed each Saturday removal. Subjects returned to the Testing Facility and the site was scored by a trained examiner just prior to the next patch application.

If a subject developed a positive reaction of a level 2 erythema or greater during the Induction phase or if, at the discretion of the Study Director, the skin response warranted a change in site, the patch was applied to a previously unpatched, adjacent site for the next application. If a level 2 reaction or greater occurred at the new site, no further applications were made. However, any reactive subjects were subsequently Challenge patch tested.

## 9.2 Challenge Phase

After a rest period of approximately 2 weeks (no applications of the test article), the Challenge patch was applied to a previously unpatched (virgin) test site. The site was scored 24 and 72 hours after application. All subjects were instructed to report any delayed skin reactivity that occurred after the final Challenge patch reading. When warranted, selected test subjects were called back to the Clinic for additional examinations and scoring to determine possible increases or decreases in Challenge patch reactivity.

Dermal responses for both the Induction and Challenge phases of the study were scored according to the following 6-point scale:

- 0 = No evidence of any effect
- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

All other observed dermal sequelae (eg, edema, dryness, hypo- or hyperpigmentation) were appropriately recorded on the data sheet and described as mild, moderate or severe.

<sup>&</sup>lt;sup>1</sup> Marzulli FN, Maibach HI. (1976) Contact allergy: predictive testing in man. *Contact Dermatitis*. 2, 1-17. Essex Testing Clinic, Inc.\_\_\_\_\_

Page 4 of 4

ETC Panel Nos.: 16024/16097

16129/16131

ETC Entry No.: 29711

## 9.0 TEST PROCEDURE (CONT'D)

## 9.3 Data Interpretation

Edema, vesicles, papules and/or erythema that persist or increase in intensity either during the Induction and/or Challenge phase may be indicative of allergic contact dermatitis. Allergic responses normally do not resolve or improve markedly at 72-96 hours.

Exceptions to typical skin reactions may occur. These may include, but not be limited to, symptoms of allergic contact sensitivity early in the Induction period to one or more test products. When this occurs in one subject, such a reaction usually suggests either an idiosyncratic response or that the subject had a pre-exposure/sensitization to the test material or component(s) of the test material or a cross-reactivity with a similar product/component. Data for such reactions will be included in the study report but will not be included in the final study analysis/conclusion of sensitization.

#### 10.0 RESULTS AND DISCUSSION

(See Table 1 for Individual Scores)

A total of 223 subjects (49 males and 174 females ranging in age from 19 to 78 years) were empanelled for the test procedure. Two hundred nineteen (219/223) subjects satisfactorily completed the test procedure on Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous). Four (4/223) subjects discontinued for personal reasons unrelated to the conduct of the study. Discontinued subject data are shown up to the point of discontinuation, but are not used in the Conclusions section of this final report.

## **Induction Phase Summary**

Test Article		Evidence of Irritation					
	0.5	1	2	3	4	Other	
NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)	0	0	0	0	0	0	No

## **Challenge Phase Summary**

Test Article		Evidence of Sensitization					
	0.5	1	2	3	4	Other	
NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)	0	0	0	0	0	0	No

There was no skin reactivity observed at any time during the course of the study.

#### 11.0 CONCLUSIONS

Under the conditions of a repeated insult (occlusive) patch test procedure conducted in 219 subjects, Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous) was "Dermatologist-Tested" and was not associated with skin irritation or allergic contact dermatitis in human subjects.

Essex Testing Clinic, Inc.	Essex	Testing	Clinic, I	nc.						
----------------------------	-------	---------	-----------	-----	--	--	--	--	--	--

ETC Panel No.: 16024 ETC Entry No.: 29711

## TABLE 1

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.	Induction Evaluation Number										Challenge Virgin Site	
No.	1	2	3	4	5_	6	7	8	9	24hr	72hr	
1	0	0	0	0	0	0	0	0	0	0	0	
2	0	0	0	0	0	0	0	0	0	0	0	
3	0	0	0	0	0	0	0	0	0	0	0	
4	0	0	0	0	0	0	0	0	0	0	0	
5	0	0	0	0	0	0	0	0	0	0	0	
6	0	0	0	0	0	0	0	0	0	0	0	
7	0	0	0	0	0	0	0	0	0	0	0	
8	0	0	0	0	0	0	0	0	0	0	0	
9	0	0	0	0	0	0	0	0	0	0	0	
10	0	0	0	0	0	0	0	0	0	0	0	
11	0	0	0	0	0	0	0	0	0	0	0	
12	0	0	0	0	0	0	0	0	0	0	0	
13 14	0	0	0	0	0	0	0	0	0	0	0	
15	0	0	0	0	0	0	0	0	0	0	0	
16	0	0	0	0	0	0	0	0	0	0	0	
17	0	0	0	0	0	0	0	0	0	0	0	
18	0	0	0	0	0	0	0	0	0	0	0	
19	0	0	0	0	0	0	0	0	0	0	0	
20	0	0 0	0 0	0	0	0	0	0	0	0	0	
21	0	0	0	0 0	0	0	0	0	0	0	0	
22	0	0	0		0	0	0	0	0	0	0	
23	0	0	0	0	0	0	0	0	0	0	0	
24	0	0	0	0 0	0	0	0	0	0	0	0	
25	0	0	0	0	0	0	0	0	0	0	0	
26	0	0	0	0	0	0	0	0	0	0	0	
27	0	0	0	0	0 0	0 0	0	0	0	0	0	
28	0	0	0	0	0	0	0	0	0	0	0	
29	0	0	0	0	0		0	0	0	0	0	
30	0	0	0	0	0	0 0	0 0	0	0	0	0	
				<u> </u>	<u> </u>	<u> </u>	U	0	0	0	0	

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

Essex Testing	Clinic, Inc.

ETC Panel No.: 16024 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.				Evalu	Inducti uation N	lumber				Chall Virgi	lenge n Site
No.	1	2	3	4	5	6	7	8	9	24hr	72hr
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	0
44	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	0
47	0	0	0	0	0	0	0	0	0	0	0
48	0	0	0	0	0	0	0	0	0	0	0
49	0	0	0	0	0	0	0	0	0	0	0
50	0	0	0	0	0	0	0	0	0	0	0
51	0	0	0	0	0	0	0	0	0	0	0
52	0	0	0	0	0	0	0	0	0	0	0
53	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	0	0
55	0	0	0	0	0	0	0	0	0	0	0

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

Essex Testing	Clinic, Inc.		

ETC Panel No.: 16097 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

No. 1 1 0 2 0 3 0	0 0	<b>3</b>	4	5					VII YI	n Site
2 0 3 0	0	0			6	7	8	9	24hr	72hr
3 0	-	_	0	0	0	0	0	0	0	0
1		0	0	0	0	0	0	0	0	0
	_	0	0	0	0	0	0	0	0	0
4 0		0	0	0	0	0	0	0	0	0
5 0		0	0	0	0	0	0	0	0	0
6 0	_	0	0	0	0	0	0	0	0	0
7 0 8 0	-	0	0	0	0	0	0	0	0	0
	_	0	0	0	0	0	0	0	0	0
_		0	0	0	0	0	0	0	0	0
10 0		0	0	0	0	0	0	0	0	0
11 0 12 0		0	0	0	0	0	0	0	0	0
13 0	-	0	0	0	0	0	0	0	0	0
14 0		0	0	0	0	0	0	0	0	0
15 0		0 0	0	0	0	0	0	0	0	0
16 0	_	0	0	0	0	0	0	0	0	0
17 0		0	0	0	0	0	0	0	0	0
18 0	_	0	0	0	0	0	0	0	0	0
19 0	0	0	0	0	0	0	0	0	0	0
20 0	0	0	0 0	0 0	0	0	0	0	0	0
21 0		0	0	0	0 0	0 0	0	0	0	0
22 0	0	0	0	0	0	0	0 0	0	0	0
23 0	Ö	0	0	0	0	0	0	0 0	0	0
24 0	Ö	0	0	0	0	0	0	0	0	0
25 0	Ö	Ö	Ö	0	0	0	0	0	0	0
26 0	Ö	Ö	0	0	0	0	0	0	0	0
27 0	0	Ö	0	0	0	0	0	0	0	0 0
28 0	Ö	ő	Ö	Ö	0	0	0	0	0	0
29 0	Ö	Ö	Ö	ő	Ö	0	Ö	0	0	0
30 0	Ŏ	ŏ	Ö	Ö	Ö	Ö	0	Ö	0	0

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

Essex	Testing	Clinic.	Inc.		

ETC Panel No.: 16097 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.				Eval	Inducti uation I	Numbe				Chal   Virgi	lenge n Site
No.	1	2	3	4	5	6	7	8	9	24hr	72hr
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	Ō
37	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	0
40	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	lo	Ō
43	0	0	0	0	0	0	0	0	0	l o	Ö
44	0	0	0	0	0	0	0	0	0	0	0
45	0	0	0	0	0	0	0	0	0	0	0
46	0	0	0	0	0	0	0	0	0	0	Ō
47	0	0	0	0	0	0	0	0	0	0	Ö
48	0	0	0	0	0	0	0	0	0	0	Ō
49	0	0	0	0	0	0	0	0	0	0	Ŏ
50	0	0	0	0	0	0	0	0	0	Ō	Ö
51	0	0	0	0	0	0	0	0	0	0	Ŏ
52	0	0	0	0	0	0	0	0	0	Ö	Ö
53	0	0	0	0	0	0	0	0	0	Ö	Ŏ
54	0	0	0	0	0	0	0	Ō	ŏ	Ö	0
55	0	0	0	0	0	0	0	Ō	0	Ö	Ö

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

ETC Panel No.: 16129 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.				Evalu		on Iumber				Chal Virgi	lenge n Site
No.	1	2	3	4	5	6	7	8	9	24hr	72hr
1	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	Ō
6	0	0	0	0	0	0	0	0	0	0	Ō
7	0	0	0	0	0	0	0	0	0	0	Ō
8	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	lo	0
11	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	O	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0
28	0	0		ontinued							
29	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0

Scale:0 = No evidence of any effect

+ = Barely perceptible (Minimal, faint, uniform or spotty erythema)

1 = Mild (Pink, uniform erythema covering most of the contact site)

2 = Moderate (Pink-red erythema uniform in the entire contact site)

3 = Marked (Bright red erythema with/without petechiae or papules)

4 = Severe (Deep red erythema with/without vesiculation or weeping)

Essex Testing	Clinic, Inc

ETC Panel No.: 16129 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.				Evalu	Inducti uation I	<b>l</b> umbe					lenge n Site
No.	1	2	3	4	5	6	7	8	9	24hr	72hr
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	0
35	0	0	0	0	0	0	0	0	0	0	0
36	0	0	0	0	0	0	0	0	0	0	0
37	0	0	0	0	0	0	0	0	0	0	0
38	0	0	0	0	0	0	0	0	0	0	0
39	0	0	0	0	0	0	0	0	0	0	Ō
40	0	0	0	0	0	0	0	0	0	0	0
41	0	0	0	0	0	0	0	0	0	0	0
42	0	0	0	0	0	0	0	0	0	0	0
43	0	0	0	0	0	0	0	0	0	0	Ō
44	0	0	0	0	0	0	0	0	0	0	Ō
45	0	0	0	0	0	0	0	0	0	0	Ō
46	0	0	0	0	0	0	0	0	0	0	Ō
47	0	0	0	0	0	0	0	0	0	0	Ō
48	0	0	0	0	0	0	0	0	0	lo	Ō
49	0	0	0	0	0	0	0	0	0	0	Ō
50	0	0	0	0	0	0	0	0	0	Ō	Ö
51	0	0	0	0	0	0	0	0	0	Ō	Ö
52	Disc	ontinuec	ł						_		•
53	0	0	0	0	0	0	0	0	0	0	0
54	0	0	0	0	0	0	0	0	0	Ö	Ö
55	0	0	0	0	0	0	0	0	0	Ō	Ö

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

ETC Panel No.: 16131 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.				Evalu	nduction N	lumber				Chal Virgi	lenge n Site
No.	1	2	3_	4	5	6	7	8	9	24hr	72hr
1	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0		ontinue					!	
18	0	0	0	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0	0

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

Essex Testing	Clinic, Inc.	

ETC Panel No.: 16131 ETC Entry No.: 29711

## TABLE 1 (CONT'D)

## **INDIVIDUAL SCORES**

## REPEATED INSULT PATCH TEST - OCCLUSIVE

Test Article: NCL Foaming Hand Soap 0424 Lot: 16-039-2 (@ 1% aqueous)

Subj.				Eval		Numbe				Chal Virgi	lenge n Site
No.	1	2	3	4	5	6	7	8	9	24hr	72hr
31	0	0	0	0	0	0	0	0	0	0	0
32	0	0	0		ontinue	ed					
33	0	0	0	0	0	0	0	0	0	0	0
34	0	0	0	0	0	0	0	0	0	0	Ö
35	0	0	0	0	0	0	0	0	0	0	Ö
36	0	0	0	0	0	0	0	0	0	0	Ö
37	0	0	0	0	0	0	0	0	0	0	Ö
38	0	0	0	0	0	0	0	0	0	0	Ö
39	0	0	0	0	0	0	0	0	0	0	Ō
40	0	0	0	0	0	0	0	0	0	0	Ö
41	0	0	0	0	0	0	0	0	Ō	Ō	Ö
42	0	0	0	0	0	0	0	0	Ō	lŏ	Ö
43	0	0	0	0	0	0	0	0	Õ	Ō	Ŏ
44	0	0	0	0	0	0	0	0	Ō	lo	Ö
45	0	0	0	0	0	0	0	Ō	Ō	Ŏ	Ö
46	0	0	0	0	0	0	0	Ō	Ö	Ŏ	Ö
47	0	0	0	0	0	0	Ō	Ö	Ö	Ŏ	Ö
48	0	0	0	0	0	0	Ō	Ö	Ŏ	Ö	0
49	0	0	0	0	0	0	Ō	Ö	Ö	Ö	0
50	0	0	0	0	0	Ō	Ö	Ö	Ŏ	ő	0
51	0	0	0	0	0	0	0	Ö	Ŏ	ő	Ö
52	0	0	0	0	0	0	Ö	Ö	Ö	Ö	0
53	0	0	0	0	Ō	Ö	Ö	Ŏ	Ö	0	0
54	0	0	0	0	0	Ō	Ö	Ö	0	0	0
55	0	0	0	0	Ō	Ö	Ö	Ö	0	0	0
56	0	0	0	Ō	Ö	Ö	ŏ	Ö	ő	0	0
57	0	Ó	Ō	Ö	Ŏ	Ö	Õ	Ö	0	0	0
58	0	0	0	0	Ö	Ö	0	0	o l	0	0

- + = Barely perceptible (Minimal, faint, uniform or spotty erythema)
- 1 = Mild (Pink, uniform erythema covering most of the contact site)
- 2 = Moderate (Pink-red erythema uniform in the entire contact site)
- 3 = Marked (Bright red erythema with/without petechiae or papules)
- 4 = Severe (Deep red erythema with/without vesiculation or weeping)

Essex	<b>Testing</b>	Clinic,	Inc.		
	_			 	 